| Biopharmaceutical benchmarks 2014 G Walsh Nature biotechnology 32 (10), 992-1000, 2014 | 1528* | 2014 |
| Post-translational modifications in the context of therapeutic proteins G Walsh, R Jefferis Nature biotechnology 24 (10), 1241-1252, 2006 | 1218 | 2006 |
| Biopharmaceutical benchmarks 2018 G Walsh Nature biotechnology 36 (12), 1136-1145, 2018 | 1040 | 2018 |
| Biopharmaceutical benchmarks 2010 G Walsh Nature biotechnology 28 (9), 917-924, 2010 | 944 | 2010 |
| Biopharmaceuticals: biochemistry and biotechnology G Walsh John Wiley & Sons, 2013 | 454 | 2013 |
| Proteins: biochemistry and biotechnology G Walsh John Wiley & Sons, 2014 | 408 | 2014 |
| Biopharmaceutical benchmarks—2003 G Walsh Nature biotechnology 21 (8), 865-870, 2003 | 383* | 2003 |
| Post-translational modifications of protein biopharmaceuticals G Walsh Drug discovery today 15 (17-18), 773-780, 2010 | 305 | 2010 |
| Biopharmaceuticals: recent approvals and likely directions G Walsh Trends in biotechnology 23 (11), 553-558, 2005 | 248 | 2005 |
| Therapeutic insulins and their large-scale manufacture G Walsh Applied microbiology and biotechnology 67, 151-159, 2005 | 215 | 2005 |
| The biotechnological potential of whey MP Ryan, G Walsh Reviews in Environmental Science and Bio/Technology 15, 479-498, 2016 | 206 | 2016 |
| Pharmaceutical biotechnology: concepts and applications G Walsh John Wiley & Sons, 2007 | 174 | 2007 |
| Identification and characterization of a phytase of potential commercial interest A Casey, G Walsh Journal of biotechnology 110 (3), 313-322, 2004 | 169 | 2004 |
| Purification and characterization of extracellular phytase from Aspergillus niger ATCC 9142 A Casey, G Walsh Bioresource Technology 86 (2), 183-188, 2003 | 168 | 2003 |
| Biological benchmarks G Walsh Nat Biotechnol 32 (10), 992-1000, 2014 | 147 | 2014 |
| Pharmaceutical biotechnology products approved within the European Union G Walsh European Journal of Pharmaceutics and Biopharmaceutics 55 (1), 3-10, 2003 | 141 | 2003 |
| Biopharmaceutical benchmarks 2022 G Walsh, E Walsh Nature Biotechnology 40 (12), 1722-1760, 2022 | 131 | 2022 |
| Second-generation biopharmaceuticals G Walsh European Journal of Pharmaceutics and Biopharmaceutics 58 (2), 185-196, 2004 | 129 | 2004 |
| Protein biotechnology. G Walsh, DR Headon | 124 | 1994 |
| The industrial production of enzymes DR Headon, G Walsh Biotechnology advances 12 (4), 635-646, 1994 | 121 | 1994 |
